PriceTargets.com logo

VolitionRx - VNRX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.00
  • Forecasted Upside: 163.50%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.76 As of 07/26/2024 01:00 AM ET
▲ +0.07 (10.16%)

This chart shows the closing price for VNRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New VolitionRx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VNRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VNRX

Analyst Price Target is $2.00
▲ +163.50% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for VolitionRx in the last 3 months. The average price target is $2.00, with a high forecast of $2.00 and a low forecast of $2.00. The average price target represents a 163.50% upside from the last price of $0.76.

This chart shows the closing price for VNRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in VolitionRx. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/27/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/16/2023Cantor FitzgeraldLower TargetOverweight ➝ Overweight$3.00 ➝ $2.00
3/16/2023EF Hutton Acquisition Co. IReiterated RatingBuy$6.00
2/1/2023BenchmarkDowngradeBuy ➝ Hold
12/19/2022EF Hutton Acquisition Co. IInitiated CoverageBuy$6.00
8/23/2022Maxim GroupLower TargetBuy$8.00 ➝ $5.00
8/15/2022AegisLower TargetBuy$9.00 ➝ $6.00
2/18/2022Cantor FitzgeraldReiterated RatingOverweight
11/16/2021AegisLower TargetBuy$10.00 ➝ $9.00
7/9/2021Cantor FitzgeraldReiterated RatingOverweight
3/9/2021Cantor FitzgeraldInitiated CoverageOverweight$8.00
1/25/2021AegisBoost TargetBuy$8.00 ➝ $10.00
10/23/2020Maxim GroupInitiated CoverageBuy$8.00
8/19/2020AegisLower TargetBuy$10.00 ➝ $8.00
8/17/2020Maxim GroupInitiated CoverageBuy$8.00
6/1/2020OppenheimerReiterated RatingBuy$7.00
5/10/2020OppenheimerInitiated CoverageBuy$7.00
5/8/2020Maxim GroupInitiated CoverageBuy$8.00
5/6/2020AegisInitiated CoverageBuy$10.00
4/24/2020Maxim GroupInitiated CoverageBuy$8.00
11/14/2019Maxim GroupReiterated RatingBuy$8.00
(Data available from 7/27/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/28/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
3/29/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/28/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/28/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/27/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
VolitionRx logo
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.
Read More

Today's Range

Now: $0.76
Low: $0.70
High: $0.77

50 Day Range

MA: N/A

52 Week Range

Now: $0.76
Low: $0.55
High: $1.40

Volume

93,959 shs

Average Volume

175,124 shs

Market Capitalization

$47.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.59

Frequently Asked Questions

What sell-side analysts currently cover shares of VolitionRx?

The following Wall Street analysts have issued stock ratings on VolitionRx in the last year: Cantor Fitzgerald, and StockNews.com.
View the latest analyst ratings for VNRX.

What is the current price target for VolitionRx?

1 Wall Street analysts have set twelve-month price targets for VolitionRx in the last year. Their average twelve-month price target is $2.00, suggesting a possible upside of 163.5%. Cantor Fitzgerald has the highest price target set, predicting VNRX will reach $2.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $2.00 for VolitionRx in the next year.
View the latest price targets for VNRX.

What is the current consensus analyst rating for VolitionRx?

VolitionRx currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VNRX will outperform the market and that investors should add to their positions of VolitionRx.
View the latest ratings for VNRX.

What other companies compete with VolitionRx?

Other companies that are similar to VolitionRx include ANGLE, bioAffinity Technologies, Epigenomics, Eternity Healthcare and Integral Diagnostics. Learn More about companies similar to VolitionRx.

How do I contact VolitionRx's investor relations team?

VolitionRx's physical mailing address is 13215 BEE CAVE PARKWAY GALLERIA OAKS B SUITE 125, AUSTIN TX, 78738. The medical research company's listed phone number is (646) 650-1351 and its investor relations email address is [email protected]. The official website for VolitionRx is www.volitionrx.com. Learn More about contacing VolitionRx investor relations.